Neurolase
London, England, United KingdomSee on the mapFounded 2025
- Seed
Neurolase is developing AI-powered technology to transform brain surgery, with a focus on improving surgical precision and patient outcomes. Its global team of clinicians, scientists and engineers is led by a neurosurgeon and an experienced healthcare entrepreneur.
- RaisedTotal raised
- $4M
- Jun 2026Latest priced round, Jun 2026
- Seed
- Investors
- 3
- Founded
- 2025
- Employees
- 1–10
reccy insights
Neurolase’s available milestones center on financing and its surgical-imaging focus; no product launches, partnerships, awards, or leadership changes are specified. On Jun 30, 2026, the company recorded a Seed round of £3 million, approximately $4.05 million using an approximate conversion. The listed investors include Empirical Ventures, The FSE Group, British Business Bank’s South West Investment Fund, Ascension Ventures, QantX, New Wave Venture Partners, and Angel Investors Bristol. The company is developing an AI-powered intraoperative imaging system intended to help neurosurgeons distinguish tumor tissue from healthy tissue during brain tumor surgery. Co-founder Babar Vaqas is identified as a consultant neurosurgeon and Chief Medical Officer, with more than 17 years of experience.
Written by reccy's AI from company sites, press and funding records · updated Nov 2026
What makes Neurolase distinct
- 01Focuses on real-time intraoperative tissue analysis for brain tumor surgery.
- 02Aims to help neurosurgeons distinguish tumor tissue from healthy tissue and map tumor boundaries during procedures.
- 03Combines clinical, scientific, and engineering expertise in a global team.
- 04Co-founder and Chief Medical Officer Babar Vaqas is a consultant neurosurgeon with more than 17 years of experience.
- 05The company’s stated mission emphasizes improving access to advanced brain technology and helping prolong lives.
Technology & products
- AI-powered intraoperative imaging system
A system in development for analyzing tissue during brain tumor surgery to help neurosurgeons identify and map tumor boundaries and distinguish cancerous from healthy tissue.
- AI-powered technology for brain surgery.
- Real-time intraoperative imaging and tissue analysis intended for use during brain tumor procedures.
- An approach designed to help identify tumor boundaries and distinguish cancerous from healthy tissue.
Research roots1
Labs and research groups this company came from or works with.
- No page yetImperial College LondonLondon, United KingdomLondon, United Kingdom · No page yetFounder affiliation
Funding
- Venture RoundAug 2026Oxford Technology
- SeedJun 2026$4MLed by Empirical Ventures, The FSE Group, British Business Bank’s South West Investment Fund, Ascension Ventures, QantX, New Wave Venture Partners, Angel Investors Bristol
Investors8
- British Business Bank’s South West Investment Fund
- New Wave Venture Partners
- Angel Investors Bristol
- Oxford Technology
About Neurolase
- Products
- AI-powered intraoperative imaging system
- Leadership
- Babar Vaqas, Chief Medical Officer
- Focus areas
- Neurotechnology, neurosurgery, medical devices, artificial intelligence, brain tumor surgery
- Headquarters
- London, England, United Kingdom
- Founded
- 2025
- Employees
- 1–10
- Status
- Active · private